缺氧反应基因SLC25A15缺陷通过重编程谷氨酰胺代谢促进肝细胞癌
研究利用大规模数据挖掘及细胞、动物和类器官模型,探讨SLC25A15在肝细胞癌进展中的作用及机制。SLC25A15在肝癌组织中表达显著降低,低表达患者预后更差;缺氧通过HNF4A下调SLC25A15,进而经SLC1A5和OGDHL重编程谷氨酰胺代谢促进肝癌进展。干扰谷氨酰胺代谢可增强SLC25A15缺陷肝癌细胞对抗PD-L1治疗的敏感性。
要点
- SLC25A15在肝癌组织中表达显著降低,低表达患者预后更差。
- 缺氧通过抑制HNF4A下调SLC25A15,经SLC1A5和OGDHL重编程谷氨酰胺代谢。
- SLC25A15缺陷肝癌细胞对谷氨酰胺剥夺和谷氨酰胺酶抑制剂更敏感,干扰谷氨酰胺代谢增强抗PD-L1疗效。
核心结论
- SLC25A15在肝细胞癌中呈缺氧反应性,低水平通过SLC1A5和OGDHL调控导致谷氨酰胺重编程,促进肝癌进展并调节细胞对抗PD-L1的敏感性。
- 阻断谷氨酰胺来源的能量供应是治疗SLC25A15缺陷肝细胞癌的潜在治疗策略。
研究设计与样本
- 研究采用大规模数据挖掘以及细胞、动物和类器官模型系统研究SLC25A15在肝细胞癌进展中的功能。
- 研究进一步分析SLC25A15参与重编程谷氨酰胺代谢的机制。
主要发现
- SLC25A15在肝癌组织中表达显著降低,低SLC25A15水平患者预后更差。
- 缺氧暴露的肝癌细胞或组织SLC25A15表达更低;肝癌组织和细胞中受缺氧抑制的转录因子HNF4A与SLC25A15呈正相关,调节HNF4A水平可改变SLC25A15 mRNA水平。
- SLC25A15上调SLC1A5增加谷氨酰胺摄取;SLC25A15缺陷肝癌细胞中谷氨酰胺反应性代谢途径增加,通过额外脂质合成为肝癌进展供能。
- 低SLC25A15水平所致氨积累抑制OGDHL表达,OGDHL是介导SLC25A15缺陷诱导谷氨酰胺代谢重编程的开关基因。
- SLC25A15缺陷肝癌细胞对谷氨酰胺剥夺和谷氨酰胺酶抑制剂更敏感;干预谷氨酰胺代谢增加SLC25A15缺陷肝癌细胞对抗PD-L1治疗的应答。
临床怎么用
- 作者认为SLC25A15可作为潜在生物标志物,指导针对谷氨酰胺剥夺的精准治疗策略开发。
- 作者指出使用谷氨酰胺利用抑制剂可增强低SLC25A15肝癌对抗PD-L1治疗的敏感性。
- 作者认为阻断谷氨酰胺来源的能量供应是治疗SLC25A15缺陷肝细胞癌的潜在治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The role of solute carrier family 25 member 15 (SLC25A15), a critical component of the urea cycle, in hepatocellular carcinoma (HCC) progression remains poorly understood. This study investigated the impact of SLC25A15 on HCC progression and its mechanisms. METHODS: We systematically investigated the function of SLC25A15 in HCC progression using large-scale data mining and cell, animal, and organoid models. Furthermore, we analyzed its involvement in reprogramming glutamine metabolism. RESULTS: SLC25A15 expression was significantly decreased in HCC tissues, and patients with low SLC25A15 levels had a poorer prognosis. Hypoxia-exposed HCC cells or tissues had lower SLC25A15 expression. A positive correlation between HNF4A, a transcription factor suppressed by hypoxia, and SLC25A15 was observed in both HCC tissues and cells. Modulating HNF4A levels altered SLC25A15 mRNA levels. SLC25A15 upregulated SLC1A5, increasing glutamine uptake. The reactive metabolic pathway of glutamine was increased in SLC25A15-deficient HCC cells, providing energy for HCC progression through additional lipid synthesis. Ammonia accumulation due to low SLC25A15 levels suppressed the expression of OGDHL (oxoglutarate dehydrogenase L), a switch gene that mediates SLC25A15 deficiency-induced reprogramming of glutamine metabolism. SLC25A15-deficient HCC cells were more susceptible to glutamine deprivation and glutaminase inhibitors. Intervening in glutamine metabolism increased SLC25A15-deficient HCC cells' response to anti-PD-L1 treatment. CONCLUSION: SLC25A15 is hypoxia-responsive in HCC, and low SLC25A15 levels result in glutamine reprogramming through SLC1A5 and OGDHL regulation, promoting HCC progression and regulating cell sensitivity to anti-PD-L1. Interrupting the glutamine-derived energy supply is a potential therapeutic strategy for treating SLC25A15-deficient HCC. IMPACT AND IMPLICATIONS: We first demonstrated the tumor suppressor role of solute carrier family 25 member 15 (SLC25A15) in hepatocellular carcinoma (HCC) and showed that its deficiency leads to reprogramming of glutamine metabolism to promote HCC development. SLC25A15 can serve as a potential biomarker to guide the development of precision therapeutic strategies aimed at targeting glutamine deprivation. Furthermore, we highlight that the use of an inhibitor of glutamine utilization can enhance the sensitivity of low SLC25A15 HCC to anti-PD-L1 therapy.
引用
- Zhang Q, Wei T, Jin W, et al. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J Hepatol. 2023. PMID: 38450598. doi:10.1016/j.jhep.2023.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。